Biosimilar Therapeutic Peptides Industry Poised for Rapid Growth, Forecast to Touch $6.11 Billion by 2030 at 11.9% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilar therapeutic peptides market from 2026–2035 with trusted insights from The Business Research Company
What long-term size projections exist for the Biosimilar Therapeutic Peptides Market covering 2026–2035?
The biosimilar therapeutic peptides market has experienced significant growth in size over recent years. It is projected to expand from $3.5 billion in 2025 to $3.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. This historical growth can be attributed to several factors including the limited availability of biosimilar peptides, a dependence on innovative peptide therapies, the increasing prevalence of cancer and metabolic disorders, a growing awareness of peptide-based treatments, and the advancement of parenteral administration methods.
The biosimilar therapeutic peptides market is projected to experience substantial expansion in the coming years. Its value is forecast to reach $6.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.9%. This anticipated growth during the forecast period is driven by several factors, including the introduction of combination and long-acting peptides, an increase in generic peptide manufacturing, wider use of transdermal delivery methods, greater investment in peptide research and development, and rising healthcare spending on peptide-based treatments. Key trends expected during the forecast timeframe encompass an escalating need for biosimilar therapeutic peptides in oncology, an increase in peptide-based treatments for metabolic and cardiovascular conditions, greater uptake of long-acting and combination peptides, the broadening of parenteral and transdermal administration pathways, and an emphasis on affordable generic peptides and their availability in developing regions.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3423&type=smp
Which Drivers Are Impacting The Competitive Landscape Of The Biosimilar Therapeutic Peptides Market?
The widespread occurrence of chronic diseases is anticipated to propel the biosimilar therapeutic peptide market. These conditions are characterized as persistent health issues necessitating ongoing management and treatment, frequently enduring for years or an individual’s entire life. The growing incidence of chronic diseases generates a greater demand for economical treatment options, positioning biosimilar therapeutic peptides as an attractive choice due to their affordability and their capacity to improve patient access and healthcare system sustainability. Market expansion is further bolstered by regulatory support and robust clinical evidence. For example, in April 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported that in 2023, approximately 194 million U.S. adults, or 76.4%, indicated they suffered from at least one chronic condition. This prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Hence, the widespread presence of chronic diseases is expected to drive the growth of the biosimilar therapeutic peptides market.
What Segments Are Identified Within The Structure Of The Biosimilar Therapeutic Peptides Market?
The biosimilar therapeutic peptides market covered in this report is segmented –
1) By Type: Innovative, Generic
2) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations
3) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders
Subsegments:
1) By Innovative: Long-Acting Peptides, Combination Peptides
2) By Generic: Monoclonal Antibodies, Hormones, Enzymes
What Upcoming Trends Are Likely To Define The Future Path Of The Biosimilar Therapeutic Peptides Market?
Leading companies in the biosimilar therapeutic peptide market are engaged in establishing a research platform aimed at optimizing peptide synthesis, boosting production efficiency, and ensuring consistent quality from the initial discovery phase through to commercialization. The Biodrug Design Accelerator, a platform dedicated to managing research processes for peptide drug discovery, is widely considered a promising frontier in the realm of new drug development. For example, in May 2023, Fujitsu Limited, a US-based toy manufacturing and entertainment company, launched this Biodrug Design Accelerator platform to expedite peptide drug discovery research. This Biodrug Design Accelerator is designed to support peptide drug discovery scientists in pharmaceutical companies by accelerating and improving the efficiency of peptide drug development, specifically through its integration of the design, make, test, analyze (DMTA) cycles, thereby enabling faster and more informed design of peptide drug candidates, alongside fostering efficient communication among scientists regarding synthesis and testing.
Which Key Players Are Driving Competition In The Biosimilar Therapeutic Peptides Market?
Major companies operating in the biosimilar therapeutic peptides market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, Takeda Pharmaceuticals Co. Ltd., Eli Lilly and Company, Novo Nordisk A/S, Apotex Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Lonza Inc., Stada Arzneimittel AG, Ipsen S.A, Biocon Biopharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Alvogen Pharma US Inc., Corden Pharma GmbH, Bachem Holding AG, PolyPeptide Laboratories Ltd.
Access The Complete Report For Deeper Market Insights:
Which Region Is Projected To Lead The Biosimilar Therapeutic Peptides Market During The Forecast Period?
North America was the largest region in the biosimilar therapeutics peptides market in 2025. Middle East is expected to be the fastest growing region in the biosimilar therapeutic peptides market report during the forecast period. The regions covered in the biosimilar therapeutic peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Biosimilar Therapeutic Peptides Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3423&type=smp
Browse Through More Reports Similar to the Global Biosimilar Therapeutic Peptides Market 2026, By The Business Research Company
Biosimilar Therapeutic Peptide Market Report 2026
Pharmaceutical Drugs And Biologics Logistics Market 2026
Therapeutic Dental Equipment Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-dental-equipment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
